MoonLake Immunotherapeutics (MLTX)

42.63 -1.03 (-2.36%) At close: 04:00PM EDT

MoonLake Immunotherapeutics

Dorfstrasse 29
Zug 6300
Switzerland
41 415108022
https://www.moonlaketx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 50

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jorge Santos da Silva	Co-Founder, CEO & Director	1.2M	N/A	1978
Dr. Kristian Reich	Co-Founder & Chief Scientific Officer	1.23M	N/A	1966
Mr. Matthias Bodenstedt	Chief Financial Officer	891.6k	N/A	1988
Mr. Oliver Daltrop	Chief Technical Officer	N/A	N/A	N/A
Nicolas Mosimann	General Counsel	N/A	N/A	N/A
Luciana Marques	Director of HR, People & Culture	N/A	N/A	N/A
Ms. Nuala Brennan	Chief Clinical Development Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Corporate governance

MoonLake Immunotherapeutics’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.